Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06427878 in Healthy Adults
NCT02391623Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06427878 in hyperlipidemia (6 cohorts), sponsored by Pfizer. Primary endpoints: Assessment of adverse events (AEs), Assessment of clinical laboratory tests and 2 more. Started Mar 2015; status: completed.
02
Drugs
PF-06427878
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02391623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391623.